Cancer
Conditions
Interventions
Case series:None
Sponsors
Affiliation of the Registrant: Cancer Hospital, Chinese Academy of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Patients with a confirmed diagnosis of malignant tumors who are undergoing or about to undergo immunotherapy. 2.Age >= 18 years. 3.Voluntarily participating and signing an informed consent form.
Exclusion criteria
Exclusion criteria: 1.Patients with unclear pathological diagnosis or those who have been ruled out for malignant tumors after examination and treatment. 2.Patients who have completed 4 or fewer cycles of immunotherapy and have explicitly decided not to proceed with further treatment. 3.Patients who have completed immunotherapy outside the hospital and lack assessment of adverse reactions.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Immune checkpoint inhibitor-related endocrine toxicity;Immune checkpoint inhibitor-related hepatotoxicity;Immune Checkpoint Inhibitor-related Gastrointestinal Toxicity;Immune Checkpoint Inhibitor-Related Pulmonary Toxicity; | — |
Secondary
| Measure | Time frame |
|---|---|
| Immune Checkpoint Inhibitor-Related Osteoarticular and Myotoxicity;Immune Checkpoint Inhibitor-Related Skin Toxicity;Immune Checkpoint Inhibitor-Related Cardiovascular Toxicity;Immune Checkpoint Inhibitor-Related Neurotoxicity;Immune Checkpoint Inhibitor-Related Nephrotoxicity;Immune checkpoint inhibitor-related reactive cutaneous capillary angiomatosis;Immune checkpoint inhibitor-related pancreatic toxicity;Immune checkpoint administrator-related hematological toxicity;Immune checkpoint inhibitor-associated ophthalmic adverse events;Immune checkpoint inhibitor-related ototoxicity;Immune checkpoint inhibitor-related cystitis; | — |
Countries
China
Contacts
Public ContactMinghua Cong
Affiliation of the Registrant: Cancer Hospital, Chinese Academy of Medical Sciences
Outcome results
None listed